Meurer and Bessen concluded that in every industry, except pharmaceuticals and biotech, publicly traded companies spend more money litigating to protect existing patents and paying fees to the U.S. Patent and Trademark Office than they earn from the same patents. (Bessen and Meurer evaluated patents issued by all publicly traded companies between 1984 and 1999.)A bit of methodology:Next, we looked